Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRU-D: Neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer
KCT0003742Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in ovarian cancer, sponsored by AstraZeneca. Started Jul 2019; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on KCT0003742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003742.